Skip to content
Their Record

Senate Roll Call 762, 119th Congress · April 23, 2026

To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.

Question before the chamber: On the Amendment

48 yea · 50 nayAmendment Rejected2 not voting or present
Democrat44 yea · 0 nay
Republican2 yea · 50 nay
Independent2 yea · 0 nay

Solid = yea, faded = nay.

The measure

S.Con.Res. 33 ↗

A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2026 and setting forth the appropriate budgetary levels for fiscal years 2027 through 2035.

Policy area: Economics and Public Finance — assigned by Library of Congress subject specialists, not by this site.

How this vote is scored

Which tracked issues this roll call counts toward, and which way a yea vote moves a member on each. Direction is decided per issue, because one bill can push two issues opposite ways.

  • Spending & BudgetDirection unreadable — not scored

    excluded:model-unclear (0.90) A deficit-neutral reserve fund to require a study has no direct fiscal expansion or restraint effect.

    Tagged by: policy-area:Economics and Public Finance

    Axis: Fiscal expansion ← → Fiscal restraint

Who voted which way

Every member recorded on this roll call, with the party they sat with at the time.

Yea (48)

Nay (50)

Not voting or present (2)

Vote records come from Voteview (voteview.com); bill titles and policy areas from the congress.gov API. See methodology for how the record was built.